Electric automaker Nio (NIO), the Tesla (TSLA) competitor, may be coming to a dealership near you in America. This move would be highly beneficial to Nio and may very well overtake electric vehicle maker Tesla in market share. NIO is…
Shares of Relief Therapeutics (OTC:RLFTF) has gained momentum again as the company affirms Zyesami COVID-19 trial. Together with it’s partner NeuroRx, these companies have breakthrough treatments for the COVID-19 coronavirus. RLFTF Stock: This week could be exciting for Relief Therapeutics…
Shares of Senseonics (SENS), a vital competitor to DexCom (DXCM) has seen it’s shares surge 240% this month. However, there is no news released by the company that would warrant a surge of 16% at the opening bell. Here’s a…
Shares of Relief Therapeutics (OTC:RLFTF) partner NeuroRx (BRPA) has risen 171% this month on anticipated data of it’s progress with COVID-19 candidate Zyesami. NeuroRx announced yesterday that they have begun Zyesami’s Phase 2/3 of the clinical investigation for treatment of…
Shares of Tyme Technologies (TYME) has surged 100% on a new COVID-19 patent that could treat the virus. The company is an emerging biotechnology company that is also developing cancer metabolism-based therapies. The company received a notification that the United…
Shares of Ocugen (OCGN) surged 55% on the execution of their distribution agreement for COVID vaccine COVAXIN by partner Bharat Biotech. The company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to…
Senseonics (SENS) is due to report earnings on February 1, 2021. The company just announced that it has closed their $115MM Bought Deal Offering of common stock with option to purchase additional shares. The Company intends to use the net…
This should be an exiting week for Relief Therapeutic (OTC:RLFTF) investors. The company is expected to release topline data results and other information during the week for their Phase 2B/3 Trial of Zyesami. According to a previous release, no drug-related…
Atossa Therapeutics (ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and COVID-19. I believe our innovative therapies and delivery methods can…
Yesterday, President Biden has signed an executive order to improve and expand access to COVID-19 treatments. This executive order will help accelerate the development of novel therapies for the most promising COVID-19 interventions. This bill comes as a means for…
